Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial.
Chin Med J (Engl)
; 134(16): 1967-1976, 2021 07 22.
Article
in En
| MEDLINE
| ID: mdl-34310400
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
COVID-19
Type of study:
Clinical_trials
Limits:
Aged
/
Humans
Language:
En
Journal:
Chin Med J (Engl)
Year:
2021
Document type:
Article
Affiliation country:
China
Country of publication:
China